CN115552023A - 一种改良型慢病毒表达载体及其构建方法与应用 - Google Patents
一种改良型慢病毒表达载体及其构建方法与应用 Download PDFInfo
- Publication number
- CN115552023A CN115552023A CN202180034496.2A CN202180034496A CN115552023A CN 115552023 A CN115552023 A CN 115552023A CN 202180034496 A CN202180034496 A CN 202180034496A CN 115552023 A CN115552023 A CN 115552023A
- Authority
- CN
- China
- Prior art keywords
- sequence
- seq
- ltr
- expression vector
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013604 expression vector Substances 0.000 title claims abstract description 81
- 241000713666 Lentivirus Species 0.000 title abstract description 48
- 238000010276 construction Methods 0.000 title description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 87
- 239000013598 vector Substances 0.000 claims abstract description 47
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 40
- 239000003623 enhancer Substances 0.000 claims abstract description 31
- 238000010367 cloning Methods 0.000 claims abstract description 19
- 239000002773 nucleotide Substances 0.000 claims description 118
- 125000003729 nucleotide group Chemical group 0.000 claims description 118
- 210000004027 cell Anatomy 0.000 claims description 68
- 230000000694 effects Effects 0.000 claims description 46
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 22
- 239000002245 particle Substances 0.000 claims description 14
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 13
- 229930189065 blasticidin Natural products 0.000 claims description 11
- 230000014509 gene expression Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000002659 cell therapy Methods 0.000 claims description 3
- 238000001415 gene therapy Methods 0.000 claims description 3
- 238000009420 retrofitting Methods 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000013612 plasmid Substances 0.000 abstract description 37
- 238000004806 packaging method and process Methods 0.000 abstract description 27
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 73
- 101800001494 Protease 2A Proteins 0.000 description 33
- 101800001066 Protein 2A Proteins 0.000 description 33
- 238000001514 detection method Methods 0.000 description 30
- 241000700605 Viruses Species 0.000 description 29
- 239000002609 medium Substances 0.000 description 20
- 229960000723 ampicillin Drugs 0.000 description 18
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 18
- 238000001962 electrophoresis Methods 0.000 description 18
- 102000040430 polynucleotide Human genes 0.000 description 14
- 108091033319 polynucleotide Proteins 0.000 description 14
- 239000002157 polynucleotide Substances 0.000 description 14
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 230000009466 transformation Effects 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 230000035939 shock Effects 0.000 description 9
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000012096 transfection reagent Substances 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 108091033409 CRISPR Proteins 0.000 description 6
- 102100034349 Integrase Human genes 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 101710091045 Envelope protein Proteins 0.000 description 4
- 101710188315 Protein X Proteins 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 101150038500 cas9 gene Proteins 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229950010131 puromycin Drugs 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 3
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 2
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 101150039808 Egfr gene Proteins 0.000 description 2
- 241000713730 Equine infectious anemia virus Species 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 108700021358 erbB-1 Genes Proteins 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 101150083327 CCR2 gene Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 241001663880 Gammaretrovirus Species 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101710145752 Serine recombinase gin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000010094 Visna Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/00041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
- Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
提供了一种慢病毒表达载体及其构建方法与应用，所述慢病毒表达载体的质粒骨架以PLVX‑Puro为基础，通过如下步骤改造完成：a.在5'LTR上游通过基因合成和亚克隆的方式加入CMV增强子和启动子；b.将原来的5'LTR更换成长度为181bps的新5'LTR(SEQ ID NO：3)；c.将原来载体上的CMV启动子更换成EFS启动子；d.将原来载体多克隆位点后面的PGK启动子删除，同时引入P2A连接子序列；e.将原来的Puro抗性更换成更短的Blasticidin抗性；f.将原来的3'LTR更换成部分删除U3的LTR(SEQ IDNO：7)。改造获得的慢病毒表达载体相比于PLVX‑Puro具有更高的包装容量。
Description
PCT国内申请，说明书已公开。
Claims (23)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020104020531 | 2020-05-13 | ||
| CN202010402053 | 2020-05-13 | ||
| PCT/CN2021/093495 WO2021228171A1 (zh) | 2020-05-13 | 2021-05-13 | 一种改良型慢病毒表达载体及其构建方法与应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115552023A true CN115552023A (zh) | 2022-12-30 |
Family
ID=78525337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180034496.2A Pending CN115552023A (zh) | 2020-05-13 | 2021-05-13 | 一种改良型慢病毒表达载体及其构建方法与应用 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20230212607A1 (zh) |
| CN (1) | CN115552023A (zh) |
| WO (1) | WO2021228171A1 (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108441516A (zh) * | 2018-03-27 | 2018-08-24 | 和元生物技术（上海）股份有限公司 | 一种慢病毒CMV-CBh双启动子改造载体构建及应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104805120A (zh) * | 2014-01-27 | 2015-07-29 | 苟德明 | 一种shRNA-Ago2共表达慢病毒RNAi载体、重组质粒及其构建方法 |
| CN105331635B (zh) * | 2015-11-05 | 2021-02-02 | 深圳大学 | 一种诱导型慢病毒表达体系及其构建方法和应用 |
-
2021
- 2021-05-13 CN CN202180034496.2A patent/CN115552023A/zh active Pending
- 2021-05-13 US US17/998,553 patent/US20230212607A1/en active Pending
- 2021-05-13 WO PCT/CN2021/093495 patent/WO2021228171A1/zh active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108441516A (zh) * | 2018-03-27 | 2018-08-24 | 和元生物技术（上海）股份有限公司 | 一种慢病毒CMV-CBh双启动子改造载体构建及应用 |
Non-Patent Citations (2)
| Title |
|---|
| JOTE T. BULCHA ET AL: "Viral vector platforms within the gene therapy landscape", SIGNAL TRANSDUCTION AND TARGETED THERAPY, vol. 06, no. 01, 8 February 2021 (2021-02-08), pages 15 - 16 * |
| 梅兴国主编: "微载体药物递送系统", 30 November 2009, 武汉：华中科技大学出版社 , 2009.11, pages: 349 - 352 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021228171A1 (zh) | 2021-11-18 |
| US20230212607A1 (en) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2856455C (en) | Scalable lentiviral vector production system compatible with industrial pharmaceutical applications | |
| Benskey et al. | Lentivirus production and purification | |
| US20240124848A1 (en) | Stable lentivirus packaging cell line and preparation method therefor | |
| JP7105875B2 (ja) | レトロウイルスベクター | |
| JP7469280B2 (ja) | レンチウイルスベクターのバイオ生産法 | |
| EP3854879A1 (en) | Method for enhancing lentivirus vector production | |
| Chang et al. | Lentiviral vectors preparation and use | |
| CN111925998A (zh) | 模拟SARS-CoV-2感染的系统及其制备方法与应用 | |
| Wolkowicz et al. | Lentiviral vectors for the delivery of DNA into mammalian cells | |
| CN116554349A (zh) | 嵌合病毒包膜糖蛋白及包含其的载体 | |
| US11066678B2 (en) | Methods of improving titer in transfection-based production systems using eukaryotic cells | |
| CN115552023A (zh) | 一种改良型慢病毒表达载体及其构建方法与应用 | |
| US20230183747A1 (en) | Stabilization of polyethyleneimine-deoxyribonucleic acid complex size and activity | |
| JP2022170641A (ja) | レンチウイルスパッケージングシステム、それにより製造されたレンチウイルス、及び、該レンチウイルスで形質導入された細胞、並びに、それを使用して宿主細胞のレンチウイルスの収率を向上させる方法 | |
| JP2023526348A (ja) | 細胞療法及び遺伝子療法のための安定したウイルスベクター産生細胞を産生するための組成物及び方法 | |
| US8841126B2 (en) | Method for gene transfer | |
| WO2015053398A1 (ja) | 高力価レトロウイルスベクター | |
| US6613569B1 (en) | Inducible packaging cell lines for lentivirus vectors | |
| CN116837031B (zh) | 一种生产慢病毒的低背景稳定生产细胞株的构建及其应用 | |
| Régulier et al. | Lentiviral-mediated gene transfer to model triplet repeat disorders | |
| Ali | Synthetic Biology Approaches to Lentiviral Packaging Cell Engineering | |
| US9228206B2 (en) | Method for gene transfer | |
| KR20230154075A (ko) | 세포 및 유전자 치료를 위한 바이러스 벡터 생성자 세포를 생성하고 최적화하기 위한 조성물 및 방법 | |
| CA3231011A1 (en) | Composition and methods for recombinant lentiviral production | |
| CN117820444A (zh) | 改造的病毒载体、慢病毒及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |